Erica DiNapoli

Erica DiNapoli is an Assistant Editor for OncLive®. She joined the company in 2020 and now assists in editing and publishing both videos and informational articles to the website; she also helps manage the social media platforms. Prior to joining MJH Life Sciences, she was a student at Monmouth University and held two marketing internships at United Teletech Financial Federal Credit Union and Trendsetter Media & Marketing.

Articles

Brody Calls for Effective Predictive Biomarker of Response to Selinexor in DLBCL

September 7th 2020

Joshua Brody, MD, discusses recent developments in DLBCL treatment, the role of selinexor, and the need for effective biomarkers of response in the space.

Strosberg Shares Key Strategies Propelling Progress in Gastrointestinal Cancers

September 3rd 2020

Jonathan Strosberg, MD, highlights key trials spanning gastrointestinal cancers, challenges faced in certain diseases, and the focus of future research efforts.

Sarcoma Experts Elucidate on Combination Chemotherapy Regimens

August 31st 2020

In a special episode of OncLive® On Air, Shiraj Sen, MD, PhD, and Roman Groisberg, MD, highlight research evaluating combination chemotherapy regimens in the evolving sarcoma treatment paradigm.

RO7198457/Atezolizumab Shows Early-Phase Promise in Advanced Solid Tumors

August 28th 2020

Juanita Lopez, PhD, discusses early findings with RO7198457 in combination with atezolizumab in patients with locally advanced or metastatic malignancies.

Emerging Approaches Seek to Expand the Relapsed/Refractory Follicular Lymphoma Treatment Arsenal

August 28th 2020

Lori A. Leslie discusses several key studies evaluating emerging approaches in the relapsed/refractory follicular lymphoma paradigm.

CDK4/6 Inhibitors Shift Standards in HR+ Metastatic Breast Cancer

August 28th 2020

Denise A. Yardley, MD, highlights the evolving role of adjuvant CDK4/6 inhibition in HR-positive metastatic breast cancer.

Trastuzumab Deruxtecan, Tucatinib Generate Excitement in Metastatic HER2+ Breast Cancer

August 27th 2020

Erika P. Hamilton, MD, discusses the pivotal data that led to the approvals of trastuzumab deruxtecan and tucatinib in metastatic HER2-positive breast cancer, factors considered in terms of treatment selection, and emerging agents under exploration.

Ocean Outlines Promise of SM-88 in Advanced Pancreatic Cancer

August 27th 2020

Allyson Ocean, MD, discusses the encouraging results from the phase II TYME-88-Panc study of SM-88 in patients with advanced pancreatic cancer.

Schwartz Hunts for Predictive Biomarkers in Soft Tissue Sarcoma

August 26th 2020

Gary K. Schwartz, MD, highlights research that is being done with regard to genomic signatures in sarcoma, challenges faced with immunotherapy, and where the field is headed.

Experts Spotlight Ongoing Efforts Evaluating Immunotherapy in Sarcoma

August 21st 2020

Despite encouraging data shown in some subtypes, there is still a lot of work that still needs to be done with determining the optimal use for immunotherapy in patients with sarcoma, a population that has historically been difficult to treat.

Randall Underscores the Need for Multidisciplinary Management of Desmoid Fibromatosis

August 21st 2020

R. Lor Randall, MD, FACS, discusses the evolving management of desmoid fibromatosis, shares advice on the factors that go into deciding when to treat this disease, and stresses the importance of having a multidisciplinary team involved in the care of these patients.

Rapid Progress in HCC Paradigm Shifts Standards, Sequencing Strategies

August 20th 2020

Bradley G. Somer, MD, discusses shifts in the hepatocellular carcinoma treatment paradigm, pivotal trials that have generated excitement, and sequencing approaches.

Rectal Cancer Treatment Enters an Era of Personalized Medicine

August 19th 2020

Noam VanderWalde, MD, MS, highlights the importance of multidisciplinary care for rectal cancer and few key studies that have impacted treatment.

Tripathy Navigates Ever-Changing HER2+ Breast Cancer Treatment Landscape

August 19th 2020

Debu Tripathy, MD, discusses tucatinib and fam-trastuzumab deruxtecan-nxki as 2 exciting drug approvals in the constantly changing HER2-positive breast cancer treatment paradigm.

ALLO-501– and ALLO-647–Based Lymphodepletion Well Tolerated in Advanced Non-Hodgkin Lymphoma

August 17th 2020

Sattva Neelapu, MD, discussed findings from the first-in-human phase 1 ALPHA study which demonstrated encouraging short-term efficacy, along with manageable toxicities, with ALLO-501 and ALLO-647.

Investigational Immunotherapies Elicit Unprecedented Responses in Relapsed/Refractory Myeloma

August 17th 2020

Nina Shah MD, discusses the future of CAR T-cell therapy and bispecific antibodies in multiple myeloma.

Experts Debate the Significance of ADAURA Data With Adjuvant Osimertinib in EGFR+ NSCLC

August 14th 2020

The phase 3 ADAURA trial continues to generate a lot conversation, debate, and excitement in the lung cancer community after results showed that adjuvant osimertinib showed a statistically significant improvement in disease-free survival in patients with stage IB-IIIA EGFR-positive non–small cell lung cancer, making it the first agent to do so in the space.

Antiandrogens Continue to Be Focus of Nonmetastatic CRPC Treatment

August 12th 2020

Atish D. Choudhury, MD, PhD, sheds light on the nonmetastatic castration-resistant prostate cancer treatment landscape and notable ongoing trials examining antiandrogens in different settings.

Intense Neoadjuvant ADT Prior to Radical Prostatectomy Leads to Promising pCRs in High-Risk Prostate Cancer

August 11th 2020

Rana R. McKay, MD, discusses the benefit of intense neoadjuvant hormone therapy prior to radical prostatectomy in men with high-risk prostate cancer and next steps for research.

Khushalani on Building Upon the Benefit Achieved With Cemiplimab in CSCC

August 11th 2020

Nikhil Khushalani, MD, discusses cemiplimab-rwlc, which has become the preferred agent for the frontline treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma.